+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell Therapy Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography- Product Image
Cell Therapy Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography- Product Image
New

Cell Therapy Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography

  • PDF Icon

    Report

  • 678 Pages
  • December 2025
  • Region: Global
  • Roots Analysis
  • ID: 5397788
Description Jump to:
The global cell therapy manufacturing market is estimated to grow from USD 4.90 billion in the current year to USD 13.83 billion by 2035, at a CAGR of 9.90% during the forecast period, till 2035.

CELL THERAPY MANUFACTURING MARKET: GROWTH AND TRENDS

The recent advancements in cellular therapies and several FDA approved cell therapies have highlighted the potential of these innovative therapies in tackling cancer, rare diseases, and chronic conditions. As a result, the healthcare sector is consistently focused more on these cell therapies. It is worth highlighting that over 1,930 clinical trials are underway to assess the effectiveness of cell therapies on different diseases globally. Moreover, several approved cell therapies have emerged as leading revenue generators within the pharmaceutical industry. For instance, Gilead Sciences has reported over USD 1.5 billion in revenue annually from the sale of Yescarta®. This cell therapy is estimated to be among the top revenue generating ATMP. Given the clinical effectiveness of cellular therapies and therapeutic potential, industry players are now focused on the development of more efficient cell therapy production methods. Currently, over 260 players are engaged in the process of cell therapy manufacturing. Notably, more than 50% of the companies within the cell therapy production supply chain are based in the US.

With the ongoing initiatives of multiple stakeholders to simplify manufacturing complexities and an increased focus on advancing these therapies, we expect robust growth in the cell therapy manufacturing market in the foreseeable future. Due to the comparatively high effectiveness of cell therapies, there is growing interest and engagement from major pharmaceutical companies in this sector. This has been vital in the growing acceptance of cell therapies.

CELL THERAPY MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the cell therapy manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Presently, over 265 industry and non-industry stakeholders are engaged in cell therapy manufacturing; more than 70% of these are industry players, with the required capability to manufacture various types of cells.
  • Immune cells and stem cells are the most prominent type of cells being manufactured by stakeholders in this industry; over 60% of the players operate at preclinical, clinical and commercial scales of operation.

  • More than 70 automation technologies are currently available for the manufacturing of cell therapies to minimize manual interventions; this is likely to attract the interest of stakeholders in the cell therapy domain.
  • In the past few years, the number of clinical studies has increased at an annualized rate of nearly 10% across the world; majority of the clinical studies are evaluating cell therapies in phase I studies.
  • The rise in partnership activity in this domain highlights the growing interest of players in the cell therapy manufacturing market; majority of the deals have been inked for the clinical manufacturing of T cell therapies.
  • To gain a competitive edge and establish themselves as one-stop shops, stakeholders are actively consolidating their capabilities related to cell therapy manufacturing through mergers and acquisitions.
  • 80% of the industry players have expanded their existing capacities and capabilities through the establishment of new facilities; among these more than 40% of facilities are dedicated to the manufacturing of T cells.

  • Nearly 50% of the big pharma initiatives have been undertaken for the purpose of expanding their portfolio and capabilities through partnerships and collaborations; among these, 70% initiatives were undertaken post-2019.
  • More than 70% of the current installed cell therapy manufacturing capacity (in terms of number of cleanrooms) is presently available with industry players; maximum capacity is installed in facilities based in North America.
  • In 2035, more than 45% of the clinical demand for cell therapies is likely to be generated by T cell therapies, including CAR-T, TCR and TIL therapies, for the treatment of patients suffering from various disorders.

  • Owing to the increased disease burden and shift in patient preferences towards tailored cell therapies, the market is poised to witness substantial growth in the next decade.
  • The cell therapy manufacturing domain is poised to grow at a CAGR of 10%; the opportunity is well distributed across different types of cell therapies, sources of cells, scale of operation, type of manufacturer and geography.

CELL THERAPY MANUFACTURING MARKET: KEY SEGMENTS

Currently, T Cell Therapy Holds Maximum Share of the Cell Therapy Manufacturing Market

Based on the type of cell therapy, the market is segmented into T cell therapies, NK cell therapies, dendritic cell therapies and stem cell therapies. It is worth highlighting that the market for dendritic cell therapies is likely to grow at a relatively faster pace (CAGR of 11.1%) in the next decade. This can be attributed to high effectiveness of dendritic cell therapies in treating oncological disorders.

At Present, Autologous Source of Cell Market Segment Captures the Largest Market Share of the Overall Cell Therapy Manufacturing Market

Based on the source of cells, the market is segmented into autologous, allogeneic, and unspecified sources. It is worth highlighting that autologous sources of cell are likely to grow at an annualized rate of 9.8% in the next decade. This can be attributed to the fact that more than 90% of the FDA approved cell therapies are derived from the patients.

Cell Therapies Manufactured at Clinical Scale is Likely to Dominate the Cell Therapy Manufacturing Market During the Forecast Period

Based on scale of operation, the market is segmented into clinical and commercial. It is worth highlighting that the cell therapies manufactured at clinical scale capture the larger share of the market and is poised to capture 58% of the revenue share by 2035. This can be attributed to the increasing number of cell therapy pipeline candidates in clinical trial phases.

Contract Manufacturing is Likely to Dominate the Cell Therapy Manufacturing Market During the Forecast Period

Based on type of manufacturer, the market is segmented into contract manufacturing and in-house manufacturing. It is worth highlighting that, currently, contract manufacturing of cell therapies holds the larger share in the cell therapy manufacturing market. This trend is unlikely to change in the coming decade. This can be attributed to the fact that contract manufacturers offer scalability and flexibility, enabling them to quickly adapt to evolving manufacturing needs and accommodate increased production volumes. In addition, by outsourcing cell therapy manufacturing operations, the drug developers can prevent significant capital investments for the establishment of in-house manufacturing facilities

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cell Therapy Manufacturing Market

  • AGC Biologics
  • BioNTech Innovative Manufacturing Services
  • Cell and Gene Therapy Catapult
  • Cell Therapies
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Centre for Cell Manufacturing Ireland, National University of Ireland
  • Charles River Laboratories
  • Clinical Cell and Vaccine Production Facility, University of Pennsylvania
  • FUJIFILM Cellular Dynamics
  • Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
  • KBI Biopharma
  • Laboratory for Cell and Gene Medicine, Stanford University
  • Lonza
  • MEDINET
  • Minaris Regenerative Medicine
  • Molecular and Cellular Therapeutics, University of Minnesota
  • Newcastle Cellular Therapies Facility, Newcastle University
  • Nikon CeLL Innovation
  • Rayne Cell Therapy Suite, King’s College London
  • RoslinCT
  • Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
  • Sydney Cell and Gene Therapy
  • Thermo Fisher Scientific
  • WuXi AppTec

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
  • Marketing Manager, Cell Therapy, Company A
  • Director, Company B
  • Marketing Director, Company C
  • Chief Commercial Officer and Executive Vice-President, Company D
  • Senior Director of Sales Advanced Therapies, Company E
  • Business Administration Department Manager, Company F
  • Chief Business Officer, Company G
  • Director of Finance and Facility Operations, Laboratory for Cell and Gene Medicine, Company H
  • Senior Director, Company I
  • Chief Executive Officer, Company J
  • Chief Technical Officer, Company K
  • Chief Executive Officer, Company L
  • General Manager, Company M
  • Chief Executive Officer, Company N
  • Executive VP Research and Development, Company O
  • Ex-Business Development Manager, Company P
  • Professor and American Red Cross Chair in Transfusion Medicine, Company Q
  • Ex- Co-Founder and Chief Executive Officer, Company R
  • Ex-Manager, Business Development & Operations-cGMP Manufacturing Unit, Company S
  • Manager of Business Development, Company T
  • Ex-Department Leader, Cell Therapy Innovation and Development, Company U
  • Ex-Chief Executive Officer, Company V
  • Chief Executive Officer, Company W

CELL THERAPY MANUFACTURING MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell therapy manufacturing market, focusing on key market segments, including [A] type of cell therapy, [B] source of cells, [C] scale of operation, [D] type of manufacturer and [E] key geographical regions.
  • Market Impact Analysis: The report analyzes various factors such as [A] drivers, [B] restraints, [C] opportunities, and [D] challenges affecting market growth.
  • Market Landscape (Industry Players): A comprehensive evaluation of companies involved in cell therapy manufacturing, considering various parameters, such as [A] company size, [B] year of establishment, [C] location of headquarters, [D] location of manufacturing facilities, [E] type of manufacturer, [F] type of cell manufactured, [G] source of cells, [H] scale of operation and [I] additional services offered.
  • Market Landscape (Non- Industry Players): A comprehensive evaluation of non-industry players involved in cell therapy manufacturing, considering various parameters, [A] such as year of establishment, [B] location of headquarters, [C] location of manufacturing facilities, [D] type of manufacturer, [E] type of cell manufactured (immune cells, stem cells and others), [F] source of cells, [G] scale of operation and [H] additional services offered.
  • Regulatory Landscape: A comprehensive discussion on regulations governing cell therapy manufacturing across different regions, including [A] North America (with an emphasis on the US), [B] Europe, and [C] Asia (highlighting Japan and China).
  • Roadmaps for Overcoming Challenges: An overview of the diverse roadmaps released by various global agencies in order to advance the cell therapy manufacturing process.
  • Automation Technologies for Cell Therapy Manufacturing: An in-depth analysis of the impact of technological automation on cell therapy manufacturing aims to enhance existing production methods by utilizing closed and single-use systems.
  • Company Profiles: Industry Players: In-depth profiles of key industry players in cell therapy manufacturing market, focusing on [A] company overviews, [B] service portfolio, manufacturing capabilities and facilities, [C] recent developments, and an informed future outlook.
  • Company Profiles: Non-Industry Players: In-depth profiles of key non-industry players in cell therapy manufacturing market, focusing on [A] organization overviews, [B] service portfolio and [C] manufacturing facilities.
  • Non-Profit Organizations in Cell Therapy Manufacturing: A comprehensive overview of non-profit organizations engaged in the manufacturing of cell therapies, including a list of organizations actively involved in the development and production of cell-based therapies across various regions
  • Clinical Trial Analysis: A detailed clinical trial analysis of completed, ongoing, and planned clinical studies based on parameters like [A] trial registration year, [B] enrolled patient population, [C] trial status, [D] trial phase, [E] type of sponsor / collaborator, [F] patient segment, [G] study design, and [H] geographical distribution of trials.
  • Partnerships and Collaborations: An analysis of partnerships established in this domain, based on several relevant parameters, such as the [A] year of partnership, [B] type of partnership, [C] type of cells manufactured, [D] scale of operation and [E] geographical distribution.
  • Recent Expansions: An examination of the different expansion efforts made by service providers in this field to enhance their cell therapy manufacturing capabilities, since 2017. This analysis considers various factors, including the [A] year of expansion, [B] type of expansion, [C] type of cells produced, [D] scale of operations, [E] location of the expanded manufacturing facilities and the [F] most active companies based on the number of expansion initiatives undertaken.
  • Big Pharma Initiatives: Assessment of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as [A] number of initiatives, [B] year of initiative, [C] purpose of initiative, [D] type of initiative, [E] scale of operation and [F] type of cell manufactured.
  • Capacity Analysis: Estimation of global cell-based therapies manufacturing capacity, derived from data provided by various industry and non-industry sources in the public domain. This analysis emphasizes the distribution of the available capacity (in terms of cleanroom area and number of cleanrooms) on the basis of [A] scale of operation, and [B] key geographical regions.
  • Demand Analysis: Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on [A] type of cell therapy and [B] key geographical regions.
  • Cost Price Analysis: An in-depth examination of the various factors that may impact the pricing of cell-based therapies, highlights the different models and strategies used by manufacturers to establish the prices of their proprietary products.
  • Make Versus Buy Decision Making Framework: A qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • Total Cost of Ownership for Cell Therapy Manufacturing Organizations: A comprehensive total cost of ownership analysis for cell therapy manufacturing organizations, categorized by company size, spanning 20 years.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading CDMOs / CMOs in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What kinds of expansion initiatives have been undertaken by industry stakeholders?
  • What are the factors that are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with the Research Team
  • Free Update if the Report is 6+ Months Old

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Cell-based Therapies
5.2.1. Comparison of Cell-based Therapies and Other Biotechnological Products
5.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
5.2.3. Current Market Landscape of ATMPs
5.3. Overview of Cell Therapy Manufacturing
5.4. Cell Therapy Manufacturing Models
5.4.1. Centralized Manufacturing
5.4.2. Decentralized Manufacturing
5.5. Scalability of Cell Therapy Manufacturing Processes
5.5.1. Scale-up
5.5.2. Scale-out
5.6. Types of Cell Therapy Manufacturers
5.7. Key Challenges for Manufacturing Cell Therapies
5.8. Key Factors Influencing Cell Therapy Manufacturing
5.8.1. Characterization
5.8.2. Cost of Goods
5.9. Automation of Cell Therapy Manufacturing Processes
5.10. Cell Therapy Manufacturing Supply Chain
5.11. Future Perspectives
6. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Industry Players: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Location of Manufacturing Facility
6.2.6. Analysis by Type of Manufacturer
6.2.7. Analysis by Location of Headquarters and Type of Manufacturer
6.2.8. Analysis by Type of Cell Manufactured
6.2.9. Analysis by Location of Headquarters and Type of Cell Manufactured
6.2.10. Analysis by Source of Cells
6.2.11. Analysis by Type of Cell Manufactured and Source of Cells
6.2.12. Analysis by Scale of Operation
6.2.13. Analysis by Additional Services Offered
6.2.14. Analysis by Company Size and Additional Services Offered
7. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Non-Industry Players: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Location of Headquarters
7.2.3. Analysis by Location of Manufacturing Facility
7.2.4. Analysis by Type of Manufacturer
7.2.5. Analysis by Location of Headquarters and Type of Manufacturer
7.2.6. Analysis by Type of Cell Manufactured
7.2.7. Analysis by Location of Headquarters and Type of Cell Manufactured
7.2.8. Analysis by Source of Cells
7.2.9. Analysis by Type of Cell Manufactured and Source of Cells
7.2.10. Analysis by Scale of Operation
7.2.11. Analysis by Additional Services Offered
8. REGULATORY LANDSCAPE
8.1. Chapter Overview
8.2. Current Scenario
8.2.1. Regulatory Guidelines in North America
8.2.2. Regulatory Guidelines in Europe
8.2.3. Regulatory Guidelines in Asia Pacific
8.2.3.1. Regulatory Guidelines in Japan
8.2.3.2. Regulatory Guidelines in China
8.2.4. Conditional Approvals
8.3. Regulatory Authorities for Cell Therapy Manufacturing
8.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
8.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
8.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
8.6. Variability in Regulatory Guidelines across Different Geographies
9. ROADMAPS FOR OVERCOMING CHALLENGES
9.1. Chapter Overview
9.2. Roadmap for the US
9.2.1. Cell Processing
9.2.2. Cell Preservation, Distribution and Handling
9.2.3. Process Automation and Data Analytics
9.2.4. Process Monitoring and Quality Control
9.2.5. Standardization and Regulatory Support
9.2.6. Workforce Development
9.2.7. Supply Chain and Logistics
9.3. Roadmaps for Other Geographies
9.3.1. Europe
9.3.2. Asia Pacific
10. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
10.1. Chapter Overview
10.2. Automation of Cell Therapy Manufacturing Processes
10.2.1. Closed Systems
10.2.2. Single-use Systems
10.2.3. Modular Systems
10.3. Growth Drivers and Roadblocks
10.4. Case Studies
10.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
10.4.2. Automating the Cell Therapy Manufacturing Process
10.5. GMP-in-a-Box
10.6. List of Automated and Closed Cell Therapy Processing Systems
10.7. Comparative Analysis of Manual and Automated Processes
11. COMPANY PROFILES: INDUSTRY PLAYERS
11.1. Chapter Overview
11.2. Service Providers in North America
11.2.1 AGC Biologics
11.2.1.1. Company Overview
11.2.1.2. Financial Information
11.2.1.3. Service Portfolio
11.2.1.4. Manufacturing Facilities and Capabilities
11.2.1.5. Recent Developments and Future Outlook
11.2.2. Charles River Laboratories
11.2.2.1. Company Overview
11.2.2.2 Financial Information
11.2.2.3. Service Portfolio
11.2.2.4. Manufacturing Facilities and Capabilities
11.2.2.5. Recent Developments and Future Outlook
11.2.3. FUJIFILM Cellular Dynamics
11.2.3.1. Company Overview
11.2.3.2. Service Portfolio
11.2.3.3. Manufacturing Facilities and Capabilities
11.2.3.4. Recent Developments and Future Outlook
11.2.4. KBI Biopharma
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. Service Portfolio
11.2.4.4. Manufacturing Facilities and Capabilities
11.2.4.5. Recent Developments and Future Outlook
11.2.5. Thermo Fisher Scientific
11.2.5.1. Company Overview
11.2.5.2. Financial Information
11.2.5.3. Service Portfolio
11.2.5.4. Manufacturing Facilities and Capabilities
11.2.5.5. Recent Developments and Future Outlook
11.2.6. WuXi Advanced Therapies
11.2.6.1. Company Overview
11.2.6.2. Service Portfolio
11.2.6.3. Manufacturing Facilities and Capabilities
11.2.6.4. Recent Developments and Future Outlook
11.3. Service Providers in Europe
11.3.1. BioNTech Innovative Manufacturing Services
11.3.1.1. Company Overview
11.3.1.2. Service Portfolio
11.3.1.3. Manufacturing Facilities and Capabilities
11.3.1.4. Recent Developments and Future Outlook
11.3.2. Cell and Gene Therapy Catapult
11.3.2.1. Company Overview
11.3.2.2. Service Portfolio
11.3.2.3. Manufacturing Facilities and Capabilities
11.3.2.4. Recent Developments and Future Outlook
11.3.3. Lonza
11.3.3.1. Company Overview
11.3.3.2. Financial Information
11.3.3.3. Service Portfolio
11.3.3.4. Manufacturing Facilities and Capabilities
11.3.3.5. Recent Developments and Future Outlook
11.3.4. RoslinCT
11.3.4.1. Company Overview
11.3.4.2. Service Portfolio
11.3.4.3. Manufacturing Facilities and Capabilities
11.3.4.4. Recent Developments and Future Outlook
11.4. Service Providers in Asia Pacific
11.4.1. Cell Therapies
11.4.1.1. Company Overview
11.4.1.2. Service Portfolio
11.4.1.3. Manufacturing Facilities and Capabilities
11.4.1.4. Recent Developments and Future Outlook
11.4.2. Minaris Regenerative Medicine
11.4.2.1. Company Overview
11.4.2.2. Service Portfolio
11.4.2.3. Manufacturing Facilities and Capabilities
11.4.2.4. Recent Developments and Future Outlook
11.4.3. MEDINET
11.4.3.1. Company Overview
11.4.3.2. Service Portfolio
11.4.3.3. Manufacturing Facilities and Capabilities
11.4.3.4. Recent Developments and Future Outlook
11.4.4. Nikon CeLL Innovation
11.4.4.1. Company Overview
11.4.4.2. Service Portfolio
11.4.4.3. Manufacturing Facilities and Capabilities
11.4.4.4. Recent Developments and Future Outlook
12. COMPANY PROFILES: NON-INDUSTRY PLAYERS
12.1. Chapter Overview
12.2. Center for Cell and Gene Therapy, Baylor College of Medicine
12.2.1. Overview
12.2.2. Service Portfolio
12.2.3. Manufacturing Facilities and Capabilities
12.3. Centre for Cell Manufacturing Ireland, National University of Ireland
12.3.1. Overview
12.3.2. Service Portfolio
12.3.3. Manufacturing Facilities and Capabilities
12.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
12.4.1. Overview
12.4.2. Service Portfolio
12.4.3. Manufacturing Facilities and Capabilities
12.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
12.5.1. Overview
12.5.2. Service Portfolio
12.5.3. Manufacturing Facilities and Capabilities
12.6. Laboratory for Cell and Gene Medicine, Stanford University
12.6.1. Overview
12.6.2. Service Portfolio
12.6.3. Manufacturing Facilities and Capabilities
12.7. Molecular and Cellular Therapeutics, University of Minnesota
12.7.1. Overview
12.7.2. Service Portfolio
12.7.3. Manufacturing Facilities and Capabilities
12.8. Newcastle Cellular Therapies Facility, Newcastle University
12.8.1. Overview
12.8.2. Service Portfolio
12.8.3. Manufacturing Facilities and Capabilities
12.9. Rayne Cell Therapy Suite, King’s College London
12.9.1. Overview
12.9.2. Service Portfolio
12.9.2. Manufacturing Facilities and Capabilities
12.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
12.10.1. Overview
12.10.2. Service Portfolio
12.10.2. Manufacturing Facilities and Capabilities
12.11. Sydney Cell and Gene Therapy
12.11.1. Overview
12.11.2. Service Portfolio
12.11.3. Manufacturing Facilities and Capabilities
13. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING
13.1. Chapter Overview
13.2. Cell Therapy Manufacturing: Non-Profit Organizations
13.2.1. CellCAN
13.2.2. Cell Therapy Manufacturing Cooperative Research Center
13.2.3. National Cell Manufacturing Consortium (NCMC)
13.2.4. California Institute of Regenerative Medicine (CIRM)
13.3. Cell Therapy Manufacturing: International Societies
14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Cell Therapies: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Tria Registration Year and Enrolled Patient Population
14.3.3. Analysis by Trial Status
14.3.4. Analysis by Trial Registration Year and Trial Status
14.3.5. Analysis by Trial Phase
14.4.6. Analysis of Number of Clinical Trials and Enrolled Patient Population by Trial Phase
14.3.7. Analysis by Type of Sponsor / Collaborator
14.3.8. Analysis by Patient Segment
14.3.9. Analysis by Study Design
14.3.10. Most Active Players: Analysis by Number of Registered Trials
14.3.11. Analysis by Number of Trials and Geography
14.3.12. Analysis by Number of Trials, Trial Status and Geography
14.3.13. Analysis by Enrolled Patient Population, Trial Status and Geography
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Cell Therapy Manufacturing: List of Partnerships
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.4. Analysis by Type of Cells
15.5. Analysis by Scale of Operation
15.6. Analysis by Region
15.6.1. Country-wise Distribution
15.6.2. Continent-wise Distribution
15.7. Most Active Players: Analysis by Number of Partnerships
15.8. Cell Therapy Manufacturing: List of Mergers and Acquisitions
15.8.1. Analysis by Year of Agreement
15.8.2. Analysis by Type of Agreement
15.8.3. Analysis by Year of Acquisition and Type of Cells
15.8.4. Analysis by Region
15.8.4.1. Country-wise Distribution
15.8.4.2. Continent-wise Distribution
15.8.4.3. Intercontinental and Intracontinental Deals
15.8.5. Ownership Change Matrix
16. RECENT EXPANSIONS
16.1. Chapter Overview
16.2. Cell Therapy Manufacturing: List of Expansions
16.2.1. Analysis by Year of Expansion
16.2.2. Analysis by Type of Expansion
16.2.3. Analysis by Type of Cell Manufactured
16.2.4. Analysis by Scale of Operation
16.2.5. Analysis by Location of Manufacturing Facility
16.2.6. Analysis by Type of Expansion and Location of Manufacturing Facility
16.2.7. Most Active Players: Analysis by Number of Expansions
16.2.8. Most Active Players: Analysis by Area of Expansion
16.2.9. Analysis by Year and Location of Manufacturing Facility
17. BIG PHARMA INITIATIVES
17.1. Chapter Overview
17.2. List of Cell Therapy Manufacturing Focused Initiatives of Big Pharma Players
17.2.1. Analysis by Number of Initiatives
17.2.2. Analysis by Year of Initiative
17.2.3. Analysis by Type of Initiative
17.2.3.1. Analysis by Type of Partnership
17.2.3.2. Analysis by Type of Expansion
17.2.4. Analysis by Types of Cells Manufactured
17.2.5. Analysis by Scale of Operation
17.2.6. Analysis of Big Pharma Players by Year of Initiative
17.2.7. Analysis by Year and Type of Initiative
17.2.8. Analysis of Big Pharma Players by Types of Cells Manufactured
17.2.9. Analysis of Big Pharma Players by Scale of Operation
17.3. Competitive Benchmarking of Big Pharmaceutical Players
17.3.1. Harvey Ball Analysis: Big Pharma Initiatives Summary
17.3.2. Spider Web Analysis: Big Pharmaceutical Players
18. CAPACITY ANALYSIS
18.1. Chapter Overview
18.2. Industry Players: Key Assumptions and Methodology
18.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
18.2.1.1. Analysis by Company Size
18.2.1.2. Analysis by Scale of Operation
18.2.1.3. Analysis by Location of Manufacturing Facility
18.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
18.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
18.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
18.2.2.1. Analysis by Company Size
18.2.2.2. Analysis by Scale of Operation
18.2.2.3. Analysis by Location of Manufacturing Facility
18.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
18.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
18.3. Non- Industry Players: Key Assumptions and Methodology
18.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
18.3.1.1. Analysis by Scale of Operation
18.3.1.2. Analysis by Location of Manufacturing Facility
18.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
18.3.2.1. Analysis by Scale of Operation
18.3.2.2. Analysis by Location of Manufacturing Facility
18.4 Concluding Remarks
19. DEMAND ANALYSIS
19.1 Chapter Overview
19.2 Scope and Methodology
19.3 Global Demand for Cell Therapy Manufacturing
19.4 Global Clinical Demand for Cell Therapy Manufacturing
19.4.1. Analysis by Type of Cell Therapy
19.4.2. Analysis by Geography
19.5. Global Commercial Demand for Cell Therapy Manufacturing
19.5.1. Commercial Demand: Analysis by Type of Cell Therapy
19.5.2. Commercial Demand: Analysis by Geography
20. COST PRICE ANALYSIS
20.1. Chapter Overview
20.2. Factors Contributing to the High Price of Cell Therapies
20.3. Pricing Models for Cell Therapies
20.3.1. Based on Associated Costs for T-Cell Therapies
20.3.2. Based on Associated Costs for Stem Cell Therapies
20.3.3. Based on Availability of Competing Products
20.3.4. Based on Target Patient Segment
20.3.5. Based on the Opinions of Industry Experts
20.4. Cell Therapy Cost Optimization
20.4.1. Role of Cost of Goods Sold
20.4.2. Role of Automation
20.5. Role of Cell Therapy Contract Manufacturing Organizations
20.6. Reimbursement-related Considerations for Cell Therapies
20.6.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies
21. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
21.1. Chapter Overview
21.2. Assumptions and Key Parameters
21.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
21.3.1. Scenario 1
21.3.2. Scenario 2
21.3.3. Scenario 3
21.3.4. Scenario 4
21.4. Concluding Remarks
22. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS
22.1. Chapter Overview
22.2. Key Parameters
22.3. Assumptions and Methodology
22.4. Sample Dataset for the Estimation of Total Cost of Ownership
22.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
22.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
22.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
22.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20
23. GLOBAL CELL THERAPY MANUFACTURING MARKET
23.1. Chapter Overview
23.2. Scope of the Forecast
23.3. Input Data and Key Assumptions
23.4. Forecast Methodology
23.5. Global Cell Therapy Manufacturing Market, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
23.5.1. Scenario Analysis
23.5.1.1 Conservative Scenario
23.5.1.2. Optimistic Scenario
23.6. Key Market Segmentations
24. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
24.3.1. T Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.3.1.1. CAR-T Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.3.1.2. TCR Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.3.1.3. TIL Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.3.2 Stem Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.3.3. Dendritic Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.3.4. NK Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation
25. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS
25.1 Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells
25.3.1 Autologous Source of Cells: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
25.3.2 Allogeneic Source of Cells: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
25.3.3 Unspecified Source of Cells: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation
26. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation
26.3.1. Clinical Scale: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
26.4. Clinical Cell Therapy Manufacturing Market, by Type of Therapy
26.4.1. Clinical Scale Manufacturing Market for T Cell Therapies, Till 2035
26.4.1.1. Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, Till 2035
26.4.1.2. Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, Till 2035
26.4.1.3. Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, Till 2035
26.4.2. Clinical Scale Manufacturing Market for NK Cell Therapies, Till 2035
26.4.2.1. Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, Till 2035
26.4.2.2. Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Geography, Till 2035
26.4.3. Clinical Scale Manufacturing Market for Dendritic Cell Therapies, Till 2035
26.4.3.1. Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, Till 2035
26.4.3.2. Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, Till 2035
26.4.4. Clinical Scale Manufacturing Market for Stem Cell Therapies, Till 2035
26.4.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, Till 2035
26.4.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, Till 2035
26.4.5. Commercial Scale: Historical Trends (Since 2022) And Forecasted Estimates (till 2035)
26.5. Commercial Cell Therapy Manufacturing Market, by Type of Cell Therapy
26.5.1. Commercial Scale Manufacturing Market for T Cell Therapies, Till 2035
26.5.1.1. Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, Till 2035
26.5.1.2. Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, Till 2035
26.5.1.3. Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, Till 2035
26.5.2. Commercial Scale Manufacturing Market for Dendritic Cell Therapies, Till 2035
26.5.2.1. Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, Till 2035
26.5.3. Commercial Scale Manufacturing Market for Stem Cell Therapies, Till 2035
26.5.3.1. Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, Till 2035
26.5.3.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, Till 2035: Distribution by Geography
26.6. Data Triangulation and Validation
27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
27.3.1. In-House Manufacturers: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
27.3.2. Contract Manufacturing Organizations: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation
28. CELL THERAPY MANUFACTURING MARKET, BY GEOGRAPHY
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Cell Therapy Manufacturing Market: Distribution by Geography
28.3.1. North America: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
28.3.2. Europe: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
28.3.3. Asia Pacific: Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
28.3.4. Rest of the World: Historical Trends (Since 2022) And Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation
29. SWOT ANALYSIS
29.1. Chapter Overview
29.2. Strengths
29.3. Weaknesses
29.4. Opportunities
29.5. Threats
29.6. Comparison of SWOT Factors
30. SURVEY ANALYSIS
30.1. Chapter Overview
30.2. Analysis by Designation of Respondents
30.3. Analysis by Type of Cell Therapy
30.4. Analysis by Scale of Operation
30.5. Analysis by Source of Cells
30.6. Analysis by Type of Cell Culture System Used
30.7. Analysis by Availability of Fill / Finish Services
31. CONCLUDING REMARKS
32. EXECUTIVE INSIGHTS
32.1. Chapter Overview
32.2. Company A
32.2.1. Company Snapshot
32.2.2. Interview Transcript: Kelly Pisarev Lord (Marketing Manager, Cell Therapy)
32.3. Company B
32.3.1. Organization Snapshot
32.3.2. Interview Transcript: Sandra Loaiza (Director)
32.4. Company C
32.4.1. Company Snapshot
32.4.2. Interview Transcript: Rikke Lyngaa (Marketing Director)
32.5. Chapter Overview
32.5. Company D
32.5.1. Company Snapshot
32.5.2. Interview Transcript: Tomasz Baran (Management Board Vice-President)
32.6. Company E
32.6.1. Company Snapshot
32.6.2. Interview Transcript: Christie Malone (Senior Director of Sales Advanced Therapies) and Sophie Bardy (Vice President of Marketing)
32.7. Company F
32.7.1. Company Snapshot
32.7.2. Interview Transcript: Azusa Kito (Business Administration Department Manager)
32.8. Company G
32.8.1. Company Snapshot
32.8.2. Interview Transcript: Kurt Gielen (Chief Business Officer)
32.9. Company H
32.9.1. Company Snapshot
32.9.2. Interview Transcript: Kathryn Melsop (Director of Finance and Facility Operations)
32.10. Company I
32.10.1. Company Snapshot
32.10.2. Interview Transcript: Takashi Yoshikawa (Senior Director)
32.11. Company J
32.11.1. Company Snapshot
32.11.2. Interview Transcript: Peter Coleman (Chief Executive Officer)
32.12. Company K
32.12.1. Company Snapshot
32.12.2. Interview Transcript: Dominic Clarke (Chief Technical Officer, Cell and Gene Therapy)
32.13. Company L
32.13.1. Company Snapshot
32.13.2. Interview Transcript: Troels Jordansen (Former Chief Executive Officer)
32.14. Company M
32.14.1. Company Snapshot
32.14.2. Interview Transcript: Gilles Devillers (President)
32.15. Company N
32.15.1. Company Snapshot
32.15.2. Interview Transcript: Wei (William) Cao (Chief Executive Officer)
32.16. Company O
32.16.1. Company Snapshot
32.16.2. Interview Transcript: Arik Hasson (Executive Vice President Research and Development)
32.17. Company P
32.17.1. Company Snapshot
32.17.2. Interview Transcript: Fiona Bellot (Former Business Development Manager)
32.18. Company Q
32.18.1. Company Snapshot
32.18.2. Interview Transcript: David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine)
32.19. Company R
32.19.1. Company Snapshot
32.19.2. Interview Transcript: Victor Lietao Li, (Former Co-Founder and Chief Executive Officer)
32.20. Company S
32.20.1. Company Snapshot
32.20.2. Interview Transcript: Arnaud Deladeriere (Former Manager, Business Development and Operations-cGMP Manufacturing Unit)
32.21. Company T
32.21.1. Company Snapshot
32.21.2. Interview Transcript: Brian Dattilo (Director of Business Development)
32.22. Company U
32.22.1. Company Snapshot
32.22.2. Interview Transcript: Mathilde Girard (Former Department Leader, Cell Therapy Innovation and Development)
32.23. Company V
32.23.1. Company Snapshot
32.23.2. Interview Transcript: Tim Oldham (Former Chief Executive Officer)
32.24. Company W
32.24.1. Company Snapshot
32.24.2. Interview Transcript: Gerard MJ Bos (Chief Executive Officer)
33. APPENDIX 1: TABULATED DATA34. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List of Figures
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Economic and Other Project Specific Consideration: Lesson Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trial Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Recent Expansions
Figure 4.6 Executive Summary: Big Pharma Initiatives
Figure 4.7 Executive Summary: Capacity Analysis
Figure 4.8 Executive Summary: Demand Analysis
Figure 4.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
Figure 5.2 Decentralized Manufacturing: Process Model
Figure 5.3 Cell Therapy Manufacturing: Type of Manufacturers
Figure 5.4 Cell Therapies: Challenges and Drivers
Figure 5.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 5.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 6.1 Industry Players: Distribution by Year of Establishment
Figure 6.2 Industry Players: Distribution by Company Size
Figure 6.3 Industry Players: Distribution by Location of Headquarters (Region)
Figure 6.4 Industry Players: Distribution by Location of Headquarters (Country)
Figure 6.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.6 Industry Players: Distribution by Location of Manufacturing Facilities (Region)
Figure 6.7 Industry Players: Distribution by Location of Manufacturing Facilities (Country)
Figure 6.8 Industry Players: Distribution by Type of Manufacturer
Figure 6.9 Industry Players: Distribution by Location of Headquarters and Type of Manufacturer
Figure 6.10 Industry Players: Distribution by Type of Cell Manufactured
Figure 6.11 Industry Players: Distribution by Type of Immune Cell Manufactured
Figure 6.12 Industry Players: Distribution by Type of Stem Cell Manufactured
Figure 6.13 Industry Players: Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 6.14 Industry Players: Distribution by Source of Cells
Figure 6.15 Industry Players: Distribution by Type of Cell Manufactured and Source of Cells
Figure 6.16 Industry Players: Distribution by Scale of Operation
Figure 6.17 Industry Players: Distribution by Additional Services Offered
Figure 6.18 Industry Players: Distribution by Company Size and Additional Services Offered
Figure 7.1 Non-Industry Players: Distribution by Year of Establishment
Figure 7.2 Non-Industry Players: Distribution by Location of Headquarters (Region)
Figure 7.3 Non-Industry Players: Distribution by Location of Headquarters (Country)
Figure 7.4 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Figure 7.5 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Figure 7.6 Non-Industry Players: Distribution by Type of Manufacturer
Figure 7.7 Non-Industry Players: Distribution by Location of Headquarters and Type of Manufacturer
Figure 7.8 Non-Industry Players: Distribution by Type of Cell Manufactured
Figure 7.9 Non-Industry Players: Distribution by Type of Immune Cell Manufactured
Figure 7.10 Non-Industry Players: Distribution by Type of Stem Cell Manufactured
Figure 7.11 Non-Industry Players: Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 7.12 Non-Industry Players: Distribution by Source of Cells
Figure 7.13 Non-Industry Players: Distribution by Type of Cell Manufactured and Source of Cells
Figure 7.14 Non-Industry Players: Distribution by Scale of Operation
Figure 7.15 Non-Industry Players: Distribution by Additional Services Offered
Figure 8.1 Industry Players: Distribution of Manufacturing Facilities by Regulatory Authorities
Figure 8.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
Figure 10.1 Key Considerations for Automating Cell Therapy Manufacturing Process
Figure 10.2 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
Figure 10.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 10.4 Advantages and Disadvantages of Single-Use System
Figure 10.5 Growth Drivers and Roadblocks to the Automated and Closed Systems
Figure 10.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 10.7 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
Figure 10.8 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
Figure 11.1 AGC Biologics: Annual Revenues, FY 2020- Q1 FY 2024 (YEN Billion)
Figure 11.2 Charles River Laboratories: Annual Revenues, FY 2020-Q1 FY 2024 (USD Billion)
Figure 11.3 Thermo Fisher Scientific: Annual Revenues, FY 2020-Q1 FY 2024 (USD Billion)
Figure 11.4 Lonza: Annual Revenues, FY 2019 Onwards (CHF Million)
Figure 12.1 Center for Cell and Gene Therapy: Service Portfolio
Figure 12.2 Center for Cell Manufacturing Ireland: Service Portfolio
Figure 12.3 Clinical Cell and Vaccine Production Facility: Service Portfolio
Figure 12.4 Guy’s and St Thomas’ GMP Facility: Service Portfolio
Figure 12.5 Laboratory for Cell and Gene Medicine: Service Portfolio
Figure 12.6 Molecular and Cellular Therapeutics: Service Portfolio
Figure 12.7 Newcastle Cellular Therapies Facility: Service Portfolio
Figure 12.8 Rayne Cell Therapy Suite, King’s College London: Service Portfolio
Figure 12.9 Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Center for Regenerative Medicine: Service Portfolio
Figure 12.10 Sydney Cell and Gene Therapy: Service Portfolio
Figure 14.1 Clinical Trial Analysis: Scope and Methodology
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2018
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2018
Figure 14.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 14.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.7 Clinical Trial Analysis: Distribution of Trial Phase by Number of Trials and Enrolled Patient Population
Figure 14.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.9 Clinical Trial Analysis: Distribution by Patient Segment
Figure 14.10 Clinical Trial Analysis: Distribution by Study Design
Figure 14.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 14.13 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Figure 14.14 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Figure 14.15 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Cells
Figure 15.5 Heat Map: Distribution by Year and Type of Cells
Figure 15.6 Partnerships and Collaborations: Distribution by Type of T-Cells
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Stem Cells
Figure 15.8 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 15.9 Partnerships and Collaborations: Distribution by Type of Cells and Scale of Operation
Figure 15.10 Partnerships and Collaborations: Country-wise Distribution
Figure 15.11 Partnerships and Collaborations: Continent-wise Distribution
Figure 15.12 Most Active Players: Distribution by Number of Partnerships
Figure 15.13 Mergers and Acquisitions: Cumulative Year-wise Trend, Since 2016
Figure 15.14 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 15.15 Mergers and Acquisitions: Year-wise Distribution by Type of Cells
Figure 15.16 Mergers and Acquisitions: Country-wise Distribution
Figure 15.17 Mergers and Acquisitions: Continent-wise Distribution
Figure 15.18 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 15.19 Mergers and Acquisitions: Ownership Change Matrix
Figure 16.1 Recent Expansions: Cumulative Year-wise Trend, Since 2017
Figure 16.2 Recent Expansions: Distribution by Type of Expansion
Figure 16.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 16.4 Recent Expansions: Distribution by Type of Cells Manufactured
Figure 16.5 Recent Expansions: Distribution by Type of Expansion and Type of Cells Manufactured
Figure 16.6 Recent Expansions: Distribution by Scale of Operation
Figure 16.7 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 16.8 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 16.9 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Figure 16.10 Most Active Players: Distribution by Number of Expansions
Figure 16.11 Most Active Players: Distribution by Area of Expansion (in sq ft)
Figure 16.12 Recent Expansions: Distribution by Year and Location of Manufacturing Facility
Figure 17.1 Big Pharma Players: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Figure 17.2 Big Pharma Players: Distribution by Year of Initiative
Figure 17.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 17.4 Big Pharma Players: Distribution by Type of Partnership
Figure 17.5 Big Pharma Players: Distribution by Type of Expansion
Figure 17.6 Big Pharma Players: Distribution by Type of Cells
Figure 17.7 Big Pharma Players: Distribution by Scale of Operation
Figure 17.8 Big Pharma Players: Distribution of Big Pharma Players by Year and Number of Initiatives
Figure 17.9 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 17.10 Big Pharma Players: Distribution of Type of Cells Manufactured
Figure 17.11 Big Pharma Players: Distribution by Scale of Operation
Figure 17.12 Harvey Ball Analysis: Big Pharma Initiatives Summary
Figure 17.13 Spider Web Analysis: Big Pharmaceutical Players
Figure 18.1 Sample Dataset Capacity of Industry Players for Cell Therapy Manufacturing (Number of Cleanrooms): Distribution by Company Size and Range of Installed Capacity
Figure 18.2 Sample Dataset Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Figure 18.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Figure 18.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 18.5 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 18.6 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Figure 18.7 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 18.8 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Figure 18.9 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation
Figure 18.10 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 18.11 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Figure 18.12 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 18.13 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Range of Installed Capacity
Figure 18.14 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 18.15 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 18.16 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
Figure 18.17 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Figure 18.18 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 19.1 Global Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Figure 19.2 Global Demand for Cell Therapies, till 2035 (in terms of Billion Cells)
Figure 19.3 Global Clinical Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Figure 19.4 Global Clinical Demand for Cell Therapies: Distribution by Type of Cell Therapy, till 2035 (in terms of Number of Patients)
Figure 19.5 Global Clinical Demand for Cell Therapies: Distribution by Geography, till 2035 (in terms of Number of Patients)
Figure 19.6 Global Commercial Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Figure 19.7 Global Commercial Demand for Cell Therapies: Distribution by Type of Cell Therapy, till 2035 (in terms of Number of Patients)
Figure 19.8 Global Commercial Demand for Cell Therapies: Distribution by Geography, till 2035 (in terms of Number of Patients)
Figure 20.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 21.1 Make versus Buy Decision Making Framework
Figure 21.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 22.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 22.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 22.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 22.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 22.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 22.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.1 Global Cell Therapy Manufacturing Market, Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 23.2 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
Figure 23.3 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
Figure 24.1 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2022, 2024 and 2035
Figure 24.2 Cell Therapy Manufacturing Market for T Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.3 T Cell Therapy Manufacturing Market for CAR-T Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.4 T Cell Therapy Manufacturing Market for TCR Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.5 T Cell Therapy Manufacturing Market for TIL Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.6 Cell Therapy Manufacturing Market for Stem Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.7 Cell Therapy Manufacturing Market for Dendritic Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.8 Cell Therapy Manufacturing Market for NK Cell Therapies: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.1 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022, 2024 and 2035
Figure 25.2 Cell Therapy Manufacturing Market for Autologous Source of Cells: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.3 Cell Therapy Manufacturing Market for Allogeneic Source of Cells: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.4 Cell Therapy Manufacturing Market for Unspecified Source of Cells: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.1 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022, 2024 and 2035
Figure 26.2 Cell Therapy Manufacturing Market for Clinical Scale: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.3 Clinical Scale Manufacturing Market for T Cell Therapies, Till 2035 (USD Million)
Figure 26.4 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, Till 2035 (USD Million)
Figure 26.5 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, Till 2035 (USD Million)
Figure 26.6 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, Till 2035 (USD Million)
Figure 26.7 Clinical Scale Manufacturing Market for NK Cell Therapies, Till 2035 (USD Million)
Figure 26.8 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, Till 2035 (USD Million)
Figure 26.9 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Geography, Till 2035 (USD Million)
Figure 26.10 Clinical Scale Manufacturing Market for Dendritic Cell Therapies, Till 2035 (USD Million)
Figure 26.11 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, Till 2035 (USD Million)
Figure 26.12 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, Till 2035 (USD Million)
Figure 26.13 Clinical Scale Manufacturing Market for Stem Cell Therapies, Till 2035 (USD Million)
Figure 26.14 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, Till 2035 (USD Million)
Figure 26.15 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, Till 2035 (USD Million)
Figure 26.16 Cell Therapy Manufacturing Market for Commercial Scale: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.17 Commercial Scale Manufacturing Market for T Cell Therapies, Till 2035 (USD Million)
Figure 26.18 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, Till 2035 (USD Million)
Figure 26.19 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, Till 2035 (USD Million)
Figure 26.20 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, Till 2035 (USD Million)
Figure 26.21 Commercial Scale Manufacturing Market for Dendritic Cell Therapies, Till 2035 (USD Million)
Figure 26.22 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, Till 2035 (USD Million)
Figure 26.23 Commercial Scale Manufacturing Market for Stem Cell Therapies, Till 2035 (USD Million)
Figure 26.24 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, Till 2035 (USD Million)
Figure 26.25 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, Till 2035 (USD Million
Figure 27.1 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer, 2022, 2024 and 2035
Figure 27.2 Cell Therapy Manufacturing Market for In-house Manufacturers: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.3 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.1 Cell Therapy Manufacturing Market: Distribution by Geography, 2022, 2024 and 2035
Figure 28.2 Cell Therapy Manufacturing Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.3 Cell Therapy Manufacturing Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.4 Cell Therapy Manufacturing Market in Asia Pacific: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 28.5 Cell Therapy Manufacturing Market in Rest of the World: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million
Figure 29.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 29.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 30.1 Survey Insights: Distribution of Respondents by Type of Organization
Figure 30.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Figure 30.3 Survey Insights: Distribution by Designation and Seniority of Respondents
Figure 30.4 Survey Insights: Distribution by Type of Cell Therapy
Figure 30.5 Survey Insights: Distribution by Scale of Operation
Figure 30.6 Survey Insights: Distribution by Source of Cells
Figure 30.7 Survey Insights: Distribution by Cell Culture System
Figure 30.8 Survey Insights: Distribution by Availability of Fill / Finish Services
Figure 31.1 Concluding Remarks: Market Landscape
Figure 31.2 Concluding Remarks: Partnerships and Collaborations
Figure 31.3 Concluding Remarks: Mergers and Acquisitions
Figure 31.4 Concluding Remarks: Recent Expansions
Figure 31.5 Concluding Remarks: Big Pharma Initiatives
Figure 31.6 Concluding Remarks: Capacity Analysis
Figure 31.7 Concluding Remarks: Demand Analysis
Figure 31.8 Concluding Remarks: Total Cost of Ownership
Figure 31.9 Concluding Remarks: Market Sizing and Opportunity Analysis (1/2)
Figure 31.10 Concluding Remarks: Market Sizing and Opportunity Analysis (2/2)\

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3P Biopharmaceuticals
  • 3SBio
  • A*STAR’s Bioprocessing Technology Institute (BTI)
  • A2 Biotherapeutics
  • A2 Healthcare
  • Abeona Therapeutics
  • Accellta
  • Achilles Therapeutics
  • Adaptate Biotherapeutics
  • Adaptimmune Therapeutics
  • Adva Biotechnology
  • Advance BioScience Laboratories (ABL)
  • Advanced Cell Therapy Laboratory (ACTL)
  • Advanced Cell Therapy Laboratory, UC San Diego Health Sciences
  • Advanced Regenerative Manufacturing Institute
  • Advent Bioservices
  • AGC Biologics
  • Agilent Technologies
  • Aglaris
  • Akron Biotech
  • Alaunos Therapeutics (formerly Ziopharm)
  • Alberta Cell Therapy Manufacturing (ACTM)
  • Allele Biotechnology and Pharmaceuticals
  • Allogene Therapeutics
  • Anemocyte
  • anicells
  • Anterogen
  • Antion Biosciences
  • apceth Biopharma
  • Appia Bio
  • ArchiMed
  • Argos Therapeutics
  • Arsenal Biosciences
  • Artiva Biotherapeutics
  • Asahi Glass
  • Ascend Gene and Cell Therapies
  • Aseptic Technologies
  • Aspen Neuroscience
  • Aspire Health Science
  • Astellas Pharma
  • Asterias Biotherapeutics
  • Astero Bio
  • ASTRAVEUS
  • Asymptote
  • Atara Biotherapeutics
  • Athersys
  • August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
  • Austrianova
  • Autolus
  • Avalon GloboCare
  • Avectas
  • Avery Therapeutics
  • Bayer
  • Be Biopharma
  • Be The Match BioTherapies
  • Bellicum Pharmaceuticals
  • Bio Elpida
  • BioCardia
  • BioCentric
  • BioCentriq
  • Bioinova
  • BioNTech
  • BioRestorative Therapies
  • BioSenic
  • BioSyngen
  • BioTherapeutics Unit, Netherlands Cancer Institute
  • bluebird bio
  • BlueRock Therapeutics
  • Bone Therapeutics
  • Boston Children's Hospital
  • Boyalife
  • BrainStorm Cell Therapeutics
  • Brammer Bio
  • BriaCell Therapeutics
  • Bristol Myers Squibb
  • Caladrius Biosciences
  • CANCER RESEARCH TECHNOLOGY (CRT)
  • CancerRop
  • Capricor Therapeutics
  • CariCord
  • Carisma Therapeutics
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Cartexell
  • CaseBioscience
  • Catalent
  • Catapult Therapy TCR (Acquired by Cell Medica)
  • Cbio
  • CCRM
  • Cedars-Sinai Biomanufacturing Center
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell and Gene Therapy Laboratory, Children’s Hospital of Philadelphia
  • Cell Manufacturing and Production
  • Cell Medica
  • Cell Tech Pharmed
  • Cell Therapies
  • Cell Therapies Core, Moffitt Cancer Center
  • Cell Therapy and Regenerative Medicine, University of Utah
  • Cell Therapy Core, Nova Southeastern University
  • Cell Therapy Manufacturing Facility, MedStar Georgetown University Hospital
  • Cell Therapy Suite, University of Birmingham
  • Cellaïon
  • Cellares
  • Cellatoz Therapeutics
  • Cell-Easy
  • Cellectis
  • Cellevolve Bio
  • Cellex Cell Professionals
  • CELLforCURE
  • Cellin Technologies
  • Cellino
  • Cellipont Bioservices
  • Cellistic
  • CellPoint
  • Cells for Sight Stem Cell Therapy Research Unit, University College London
  • Cellular Biomedicine Group
  • Cellular Therapy Core, Sidney Kimmel Comprehensive Cancer Center
  • Cellular Therapy Core, University of Texas
  • Cellular Therapy Integrated Services, Case Western Reserve University
  • Celonic
  • Celularity
  • Celyad Oncology
  • Center for Biomedical Engineering and Advanced Manufacturing, McMaster
  • Center for Breakthrough Medicines
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Center for Cellular Immunotherapies
  • Center for International Blood and Marrow Transplant Research
  • Centre for Biological Engineering, Loughborough University
  • Centre for Cell and Gene Tissue Therapeutics, Royal Free Hospital London
  • Centre for Cell and Vector Production
  • Centre for Cell Manufacturing Ireland, NUI Galway
  • Centre for Commercialization of Cancer Immunotherapy (C3i)
  • Centre for Stem Cell Research (CSCR), Christian Medical College
  • Century Therapeutics
  • Cesca Therapeutics
  • cGMPnow
  • CHA Biolab
  • CHA Biotech
  • Charles River Laboratories
  • Chart Industries
  • Chiesi Farmaceutici
  • Children's GMP, St. Jude Children's Research Hospital
  • Children's National Hospital
  • Chimeric Therapeutics
  • China Life Health Industry Group
  • China Regenerative Medicine International
  • City of Hope
  • Clean Cells
  • Clinical Biomanufacturing Facility, University of Oxford
  • Clinical Cell and Vaccine Production Facility
  • CMIC Group
  • CO.DON
  • Cogent Biosciences
  • Cognate BioServices
  • CoImmune
  • Comprehensive Cell Solutions™
  • Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF)
  • Cook MyoSite
  • CPI
  • Creative Biolabs
  • Crescendo Biologics
  • CRISPR Therapeutics
  • Cryoport
  • CSIRO
  • CTM CRC
  • CUORiPS
  • Cynata Therapeutics
  • Cytiva
  • Cytonet
  • Cytosen Therapeutics
  • Cytovance Biologics
  • Daiichi Sankyo
  • David and Etta Jonas Center for Cellular Therapy, UChicago Medicine
  • DCPrime
  • Deep Science Ventures
  • Delphi Genetics
  • Dendreon
  • Dendreon Pharmaceuticals
  • Draper
  • Duke-NUS Medical School
  • ElevateBio
  • Emory Cellular and Immunotherapy Core (ExCITE)"
  • Empirica Therapeutics (Acquired by Century Therapeutics)
  • ENABLE SPARKS Cells
  • ERYTECH Pharma
  • Esco Aster
  • Esco VacciXcell
  • Eucardi
  • EUFETS
  • Eutilex
  • Exacis Biotherapeutics
  • Excellos
  • ExCellThera
  • eXmoor Pharma
  • Expression Therapeutics
  • FamiCord
  • Fate Therapeutics
  • Flaskworks (Acquired by Northwest Biotherapeutics)
  • FloDesign Sonics
  • Forecyte Bio
  • Formula Pharmaceuticals
  • Fosun Pharma
  • Fraunhofer Institute for Cell Therapy and Immunology
  • Fred Hutchinson Cancer Research Center
  • French Blood Agency
  • Fresenius Kabi
  • Froceth
  • FUJIFILM Cellular Dynamics
  • FUJIFILM Diosynth Biotechnologies
  • FutureGen Biopharm
  • Gamida Cell
  • GammaDelta Therapeutics
  • Gates Biomanufacturing Facility
  • GC Cell
  • GE Healthcare Life Sciences
  • GenCure
  • Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • Genentech
  • Genexine
  • Genezen
  • GenIbet Biopharmaceuticals
  • GenIbet Biopharmaceuticals (acquired by Recipharm)
  • German Red Cross Blood Donor Service
  • Ghent University
  • GI Cell
  • Gilead Sciences
  • GlaxoSmithKline
  • Glycostem Therapeutics
  • Glycotope
  • GPB Scientific
  • Gracell Biotechnologies
  • Great Ormond Street Hospital Cellular Therapy Laboratories, University College of London
  • GX Acquisition
  • H. Lee Moffitt Cancer Center and Research Institute
  • Haemonetics
  • Harvard University Stem Cell Institute
  • Health Sciences Authority (HSA)
  • Hebei Senlang Biotechnology
  • Helixmith
  • Hemostemix
  • Histocell
  • Hitachi Chemical
  • Holostem Terapie Avanzate
  • Human Cellular Therapy Laboratory, Mayo Clinic
  • Human Islet and Cellular Transplant Facility
  • I Peace
  • IASO Biotherapeutics
  • Immatics
  • ImmPACT Bio
  • ImmuneCyte
  • Immuneel Therapeutics
  • ImmunityBio
  • Immunomic Therapeutics
  • Immunovative Therapies
  • Immusoft
  • Imugene
  • Inceptor Bio
  • IncoCell Tianjin
  • Indapta Therapeutics
  • Innovative Cellular Therapeutics
  • Instil Bio
  • Intellia Therapeutics
  • Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  • International Stem Cell Corporation
  • Invetech
  • Iovance Biotherapeutics
  • IQVIA Cell And Gene Therapy Center
  • IsoPlexis
  • Ixaka
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • Japan Tissue Engineering
  • Jiuzhitang Maker Cell Technology
  • John Goldman Centre for Cellular Therapy, Imperial College London
  • Juno Therapeutics
  • JW CreaGene
  • JW Therapeutics
  • Kadimastem
  • KAEDI
  • Kangstem Biotech
  • Karolinska Institutet
  • Kawasaki Heavy Industries
  • KBI Biopharma
  • Kemwell Biopharma
  • Kiadis Pharma
  • King's Clinical Research Facility
  • Kite Pharma
  • KOLON Biotech
  • Krembil Cell Facility, St. Michael’s Hospital
  • KSQ Therapeutics
  • Laboratory for Cell and Gene Medicine, University of Stanford
  • Legend Biotech
  • Limula
  • Lineage Cell Therapeutics
  • Lion TCR
  • Longeveron
  • Lonza
  • Lorem Cytori
  • LumaCyte
  • Lyell Immunopharma
  • Lykan Bioscience
  • Lykan Bioscience (Merged with RoslinCT)
  • Lymphotec
  • Marker Therapeutics
  • Massachusetts General Hospital
  • MaSTherCell
  • Matica Biotechnology
  • MaxiVAX
  • MD Anderson Cancer Center
  • Medace
  • Medeor Therapeutics
  • Medera
  • Medigene
  • MEDINET
  • MEDIPOST
  • MedTherapy
  • Membio
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merck Millipore
  • Mesoblast
  • MicrofluidX
  • Midwest Stem Cell Therapy Center, University of Kansas Medical Center
  • Miltenyi Biotec
  • Minaris Regenerative Medicine
  • MiNK Therapeutics
  • Minovia Therapeutics
  • Molecular and Cellular Therapeutics, University of Minnesota
  • MolMed
  • Mustang Bio
  • Nagoya University
  • Nanjing Cenbest
  • NantKwest
  • NantKwest (acquired by Immunity Bio)
  • National Cancer Institute
  • National Eye Institute
  • National Resilience
  • Ncardia
  • Neogene Therapeutics
  • Neon Therapeutics
  • NeoProgen
  • New Jersey Innovation Institute (NJII)
  • Newcastle Advanced Therapies
  • NextCell Pharma
  • NHS Blood and Transplant
  • NIHR Clinical Research Facility (CRF) at Guy’s and St Thomas’
  • Nikon CeLL innovation
  • Nippon Shinyaku
  • Nipro
  • NiSCELL
  • Nkarta
  • NKGen Biotech (Formerly known as NKMax America)
  • Nohla Therapeutics
  • Noile-Immune Biotech
  • Northwest Biotherapeutics
  • Notch Therapeutics
  • Novadip Biosciences
  • Novartis
  • Novartis Gene Therapies
  • Novex Innovations
  • Novo Nordisk
  • ObiO Technology
  • Octane Biotech
  • OmniaBio
  • ONK Therapeutics
  • Ono Pharmaceutical
  • Ontario Institute for Regenerative Medicine
  • Opexa Therapeutics
  • Orca Bio
  • OrganaBio
  • Orgenesis
  • Ori Biotech
  • Ospedale Pediatrico Bambino Gesù
  • OSPIN
  • Overland Pharmaceuticals
  • Ovizio Imaging Systems
  • Oxford MEStar
  • OXGENE
  • Pall Corporation
  • PanCryos
  • Parker Institute for Cancer Immunotherapy
  • PCT
  • Performance Cell Manufacturing
  • PersonGen BioTherapeutics
  • PharmaBio
  • PharmaCell
  • Pharmaron
  • Pharmicell
  • pHion Therapeutics
  • Pierre Fabre
  • Pluristem Therapeutics
  • Poseida Therapeutics
  • Precision BioSciences
  • Promethera Biosciences
  • Provia Laboratories
  • Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
  • QIMR Berghofer Medical Research Institute
  • QuaCell Biotechnology
  • Quell Therapeutics
  • Rayne Cell Therapy Suite
  • RD-BIOTECH
  • Recipharm
  • Regenerative Medicine Center, Utrecht University
  • Regeneus
  • ReNeuron
  • Rentschler ATMP
  • Rentschler Biopharma
  • Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • Rexgenero
  • RheinCell Therapeutics (Acquired by Catalent)
  • Rivaara Immune
  • Riyadh Pharma
  • Robertson Clinical and Translational Cell Therapy, Duke University
  • RoosterBio
  • RoslinCT
  • Rubius Therapeutics
  • Rutgers Cancer Institute of New Jersey
  • S.Biomedics
  • Saint-Gobain
  • SAKARTA
  • Sana Biotechnology
  • SanBio
  • Sangamo Therapeutics
  • Sanpower
  • Sartorius
  • SCG Cell Therapy
  • Scinogy
  • Scinus Cell Expansion
  • SCM Lifescience
  • Scottish National Blood Transfusion Service
  • SCTbio
  • Secarna Pharmaceuticals
  • Senti Biosciences
  • Servier
  • Shanghai Ucardi Biomedical Technology
  • Sheba Medical Center
  • Shibuya
  • Shinshu University
  • Shoreline Biosciences
  • SingCell
  • Skeletal Cell Therapy Support (Acquired by Catalent)
  • Sonoma Biotherapeutics
  • Sorrento Therapeutics
  • SOTIO
  • Southwest Research Institute
  • S-RACMO
  • Stanford University School of Medicine
  • Stem Cell Institute
  • STEMCELL Technologies
  • Stemedica Cell Technologies
  • Stemmatters
  • Stempeutics Research
  • Sumitomo Dainippon Pharma
  • Sumitomo Pharma
  • Suzhou Porton Biologics
  • Sydney Cell and Gene Therapy
  • Syngen Biotech
  • Takara Bio
  • Takeda
  • TapImmune
  • TC BioPharm
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • Terumo Blood and Cell Technologies
  • Tessa Therapeutics
  • Tevogen Bio
  • The Discovery Labs Center for Breakthrough Medicines
  • The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • The Netherlands Cancer Institute
  • The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen)
  • The Ottawa Hospital Research Institute
  • The Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • The University of Texas MD Anderson Cancer Center
  • Therabest
  • Theragent
  • Therapeutic Cell Production Core, Seattle Children's Hospital
  • Therapeutic Cell Production Facility, Roswell Park Comprehensive Cancer Center
  • Thermo Fisher Scientific
  • ThermoGenesis
  • TiGenix
  • Tissue Genesis
  • T-knife
  • Tmunity Therapeutics
  • TrakCel
  • Treadwell Therapeutics
  • TreeFrog Therapeutics
  • Triumvira Immunologics
  • Trizell
  • TVAX Biomedical
  • TxCell
  • UC Davis GMP Laboratory
  • UCLA Human Gene and Cell Therapy
  • Umoja Biopharma
  • Universal Cells
  • University Hospital Basel
  • University of Chicago Medicine
  • University of North Carolina Lineberger Comprehensive Cancer Center
  • Upstate Stem Cell cGMP Facility (USCGF), University of Rochester
  • UW Program for Advanced Cell Therapy (PACT)
  • Vanrx Pharmasystems
  • Vecura
  • Vericel
  • Vineti
  • Vinta Bio
  • Viscofan BioEngineering
  • VivaBioCell
  • Vor Biopharma
  • Waisman Biomanufacturing
  • Wilson Wolf Manufacturing
  • Wugen
  • WuXi Advanced Therapies
  • Xellera Therapeutics
  • Xintela
  • Zelluna Immunotherapy

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions - Product Image

Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions

  • Report
  • 250 Pages
  • Global
From
Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-Users and Key Geographical Regions - Product Image

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-Users and Key Geographical Regions

  • Report
  • 343 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region, 2025-2035 - Product Image

CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region, 2025-2035

  • Report
  • Global
From
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Cell Therapy Raw Materials Global Market Insights 2026, Analysis and Forecast to 2031 - Product Image

Cell Therapy Raw Materials Global Market Insights 2026, Analysis and Forecast to 2031

  • Report
  • 87 Pages
  • Global
From

About the Cell Therapy Manufacturing Market

Cell therapy manufacturing is a biotechnology process that involves the production of cells for therapeutic use. This process involves the isolation, expansion, and differentiation of cells from a variety of sources, such as stem cells, primary cells, and cell lines. The cells are then used to treat a variety of diseases, including cancer, autoimmune diseases, and genetic disorders. Cell therapy manufacturing is a rapidly growing field, with new technologies and techniques being developed to improve the efficiency and safety of the process. Cell therapy manufacturing is a complex process that requires specialized equipment and expertise. It involves the use of a variety of techniques, such as cell culture, gene editing, and cell sorting. The process also requires the use of specialized reagents and media to ensure the quality and safety of the cells. Companies in the cell therapy manufacturing market include Thermo Fisher Scientific, Merck KGaA, Lonza Group, GE Healthcare, and Sartorius AG. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.